Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06717438 · ClinicalTrials.gov registry record · Phase 2
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
A Phase 2 study of Jordan's Syndrome and PPP2R5D Neurodevelopmental Disorder, sponsored by Shionogi.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06717438: Active Phase 2 study of Jordan's Syndrome and PPP2R5D Neurodevelopmental Disorder, sponsored by Shionogi.
NCT06717438 is a Phase 2 study of Jordan's Syndrome and PPP2R5D Neurodevelopmental Disorder that is active but no longer recruiting, run by Shionogi. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06717438, a Phase 2 study of Jordan's Syndrome and PPP2R5D Neurodevelopmental Disorder, is active but no longer recruiting, sponsored by Shionogi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BPN14770
Study Locations (3)
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
What the registry record for NCT06717438 still lists
NCT06717438 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Jordan's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06717438 reports a single indexed study location in Illinois, Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT06717438 about?
NCT06717438 is a clinical study titled "Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])". The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
What is the current status of trial NCT06717438?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-05-13. Estimated completion is 2030-01-31.
What conditions does trial NCT06717438 study?
This clinical trial studies the following conditions: Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder.
What interventions are being tested in trial NCT06717438?
The interventions under investigation include: Placebo (DRUG), BPN14770 (DRUG).
Who is sponsoring clinical trial NCT06717438?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06717438 being conducted?
This trial has 3 study locations across Illinois, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06717438's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI